Cancer Immunotherapy Winter School (CIWS)

4.0 PROJECT SUMMARY/ABSTRACT Established in 1984, the Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. The mission of SITC is to improve cancer patient outcomes by

advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field. At the forefront of SITC’s educational charge is the Cancer Immunotherapy Winter School (CIWS) program. The 2022 program in

Austin, TX will focus on delivering a program designed to enable basic, clinical, or translational scientists and clinicians from the entire cancer care team including those from diverse and underrepresented groups in biomedical sciences, to advance scientific discoveries and clinical applications of tumor immunology and

cancer immunotherapy. This comprehensive, five-day accredited CME-/CNE-/CPE-/MOC-certified program will provide a deep understanding of the core principles of tumor immunology, cancer immunotherapy and developing areas in the field. With 51 topics including foundational immunology, clinical trial design,

combination therapies, biomarker integration and data analysis, attendees have a number of session types (all- attendee, breakout, research/clinical tracks) tailored to maximize learning opportunities and styles through selection of sessions most relevant to their educational needs. This allows for many opportunities of

personalized interaction between attendees and experts. Attendees, through small group sessions and networking roundtables, will expand their professional network, developing new relationships with faculty and other thought leaders. These hands-on sessions will provide valuable networking and mentorship

opportunities, and poise questions from their own experiences. Designed and approved by experts across the healthcare spectrum—clinical physicians, nurses, pharmacists, emergency physicians, and patient advocates—establishes that all points of view are incorporated. For attendees of in-person courses, enduring

materials are available following the program and will serve as reinforcement of their learnings and allow access to other concurrent sessions they could not attend. Materials are available to the public six months later at a nominal fee. SITC, program organizers, and faculty certifies the CIWS is open to all who wish to attend

and it is a safe and respectful learning environment free from all forms of discrimination and harassment. Low registration rates, travel awards, ADA-compliant facilities, and a centralized location ensures that obstacles do not stand in the way of physicians’ knowledge and eventual use of these revolutionary treatments. SITC is

uniquely poised to hold this premier, educational option for all healthcare professionals and every type of learner. NIH support for this program will allow for continued educational and professional advancement for the entire cancer care team, in addition to networking opportunities with peers and leaders in the field.